In	O
vivo	O
effects	O
of	O
insulin	O
on	O
tumor	B-Cancer
and	O
skeletal	B-Organ
muscle	I-Organ
glucose	O
metabolism	O
in	O
patients	O
with	O
lymphoma	B-Cancer
.	O

BACKGROUND	O
:	O
The	O
anabolic	O
properties	O
of	O
insulin	O
have	O
been	O
suggested	O
for	O
use	O
to	O
reverse	O
malnutrition	O
associated	O
with	O
cancer	B-Cancer
.	O

The	O
host	O
and	O
tumor	B-Cancer
sensitivities	O
to	O
insulin	O
are	O
critical	O
for	O
such	O
treatments	O
,	O
which	O
aim	O
to	O
improve	O
patient	O
nutrition	O
.	O

The	O
authors	O
studied	O
insulin	O
effects	O
on	O
tumor	B-Cancer
and	O
skeletal	B-Organ
muscle	I-Organ
metabolism	O
with	O
2	O
-	O
[	O
18F	O
]	O
-	O
fluoro	O
-	O
2	O
-	O
deoxy	O
-	O
D	O
-	O
glucose	O
(	O
[	O
18F	O
]	O
FDG	O
)	O
and	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
.	O

METHODS	O
:	O
Six	O
patients	O
with	O
lymphoma	B-Cancer
twice	O
underwent	O
[	O
18F	O
]	O
FDG	O
-	O
PET	O
imaging	O
:	O
once	O
after	O
fasting	O
overnight	O
and	O
once	O
during	O
euglycemic	O
hyperinsulinemic	O
clamp	O
.	O

The	O
dynamic	O
uptake	O
of	O
the	O
glucose	O
analogue	O
[	O
18F	O
]	O
FDG	O
was	O
measured	O
in	O
diseased	B-Multi-tissue_structure
nodes	I-Multi-tissue_structure
and	O
upper	B-Organ
arm	I-Organ
skeletal	I-Organ
muscle	I-Organ
in	O
both	O
metabolic	O
states	O
.	O

The	O
[	O
18F	O
]	O
FDG	O
uptake	O
in	O
muscle	B-Organ
and	O
the	O
whole	O
body	B-Organism_subdivision
glucose	O
use	O
during	O
euglycemic	O
hyperinsulinemic	O
clamp	O
were	O
compared	O
with	O
those	O
of	O
weight	O
-	O
matched	O
healthy	O
subjects	O
studied	O
under	O
similar	O
circumstances	O
.	O

RESULTS	O
:	O
In	O
lymphomatous	B-Tissue
tissue	I-Tissue
,	O
[	O
18F	O
]	O
FDG	O
uptake	O
rates	O
were	O
similar	O
in	O
overnight	O
fasting	O
and	O
euglycemic	O
hyperinsulinemic	O
clamp	O
(	O
38	O
+	O
/	O
-	O
10	O
versus	O
41	O
+	O
/	O
-	O
9	O
mumol	O
/	O
100	O
g	O
/	O
minute	O
,	O
not	O
significant	O
)	O
,	O
whereas	O
glucose	O
uptake	O
in	O
skeletal	B-Organ
muscle	I-Organ
was	O
increased	O
by	O
insulin	O
(	O
1	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
2	O
versus	O
3	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
5	O
mumol	O
/	O
100	O
g	O
/	O
minute	O
,	O
P	O
=	O
0	O
.	O
012	O
)	O
.	O

Both	O
basal	O
(	O
2	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
2	O
mumol	O
/	O
100	O
g	O
/	O
minute	O
,	O
P	O
=	O
0	O
.	O
061	O
)	O
and	O
insulin	O
-	O
stimulated	O
(	O
8	O
.	O
5	O
+	O
/	O
-	O
1	O
.	O
9	O
mumol	O
/	O
100	O
g	O
/	O
minute	O
,	O
P	O
=	O
0	O
.	O
055	O
)	O
skeletal	B-Multi-tissue_structure
arm	I-Multi-tissue_structure
muscle	I-Multi-tissue_structure
glucose	O
uptake	O
rates	O
were	O
higher	O
in	O
control	O
subjects	O
than	O
in	O
patients	O
.	O

Whole	O
body	B-Organism_subdivision
glucose	O
use	O
was	O
55	O
%	O
lower	O
in	O
patients	O
than	O
in	O
control	O
subjects	O
(	O
17	O
+	O
/	O
-	O
3	O
mumol	O
/	O
kg	O
/	O
minute	O
versus	O
38	O
+	O
/	O
-	O
3	O
mumol	O
/	O
kg	O
/	O
minute	O
,	O
P	O
=	O
0	O
.	O
002	O
)	O
,	O
consistent	O
with	O
insulin	O
resistance	O
in	O
cancer	B-Cancer
.	O

CONCLUSIONS	O
:	O
We	O
found	O
that	O
insulin	O
does	O
not	O
induce	O
major	O
changes	O
in	O
glucose	O
uptake	O
of	O
lymphomatous	B-Tissue
tissue	I-Tissue
.	O

Although	O
insulin	O
sensitivity	O
of	O
skeletal	B-Organ
muscle	I-Organ
was	O
also	O
reduced	O
in	O
patients	O
with	O
lymphoma	B-Cancer
,	O
the	O
net	O
insulin	O
effect	O
may	O
counteract	O
imbalance	O
between	O
glucose	O
uptake	O
of	O
tumor	B-Cancer
and	O
muscle	B-Organ
,	O
offering	O
a	O
potential	O
means	O
to	O
circumvent	O
at	O
least	O
some	O
metabolic	O
abnormalities	O
found	O
in	O
cancer	B-Cancer
.	O

